^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Promitil (pegylated liposomal mitomycin-c prodrug)

    i
    Associations
    News

    Trials

    Company:
    LipoMedix
    Drug class:
    DNA synthesis inhibitor, Alkylating agent
    Related drugs:
    Associations
    News

    Trials

    Apply
    Promitil Treatment of Patients With Solid Tumors Associated With Deleterious Mutations Who Have Progressed After Therapy (NCT06478862)
    Phase 2
    Lipomedix Pharmaceuticals Inc.
    Recruiting
    Last update posted :
    02/05/2025
    Initiation :
    06/13/2024
    Primary completion :
    06/01/2026
    Completion :
    01/01/2027
    BRCA
    |
    Promitil (pegylated liposomal mitomycin-c prodrug)
    Intravenously Administered Pegylated Liposomal Mitomycin-C Lipid-based Prodrug (PROMITIL) in Cancer Patients With Solid Tumors. (NCT01705002)
    Phase 1
    Lipomedix Pharmaceuticals Inc.
    Completed
    Last update posted :
    07/10/2018
    Initiation :
    10/01/2012
    Primary completion :
    11/01/2017
    Completion :
    06/01/2018
    KRAS
    |
    RAS wild-type
    |
    Avastin (bevacizumab) • capecitabine • Promitil (pegylated liposomal mitomycin-c prodrug)